TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04560907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aquablation
Description: By means of a high-pressure saline stream, parenchymal tissue of the prostate is removed endoscopically through a heat-free mechanism called hydrodissection. The intervention is supported by live ultrasound guidance and the required depth as well as the angle of the resection is planned out prior to the resection. The bladder is accessed using a 24-Fr hand-piece, which accommodates the scope. The handpiece is supported by an articulating arm attached to the operation table. Once placed in the optimal position, the system automatically adjusts the alignment as necessary.~Hemostasis is consecutively achieved through diathermy and post procedure, a threeway catheter is inserted and bladder irrigation is initiated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP
Description: This is done endoscopically under general anesthesia the three lobes of the prostate that are cored out intact with the laser are pushed into the bladder before being morcellated by a special instrument inserted through the telescopic camera. A catheter is placed into the bladder to drain the urine while the raw surface heals, then left in place for around 24 hours before being removed on the day of discharge from hospital. Sterile saline fluid is also irrigated into the bladder through the catheter to dilute any blood in the urine and prevent clots from forming.
Study: NCT05737160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Administered as an SC infusion
Study: NCT05934318

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: Twice daily 6.0 g sachet, each containing 5.00 g of quality-assured L-citrulline powder, 0.66 g maltodextrin and 0.30 g lactose anhydrous, 0.03 g citric acid, 0.01 g lemon flavour + antenatal standard of care with enhanced monitoring
Study: NCT05737160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an SC infusion
Study: NCT06018428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-914
Description: Subcutaneous administration of ADX-914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration of placebo
Study: NCT05163561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A
Description: SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B
Description: SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C
Description: SII Inactivated Salk Polio Vaccine (Adsorbed) produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). It is a highly purified, adjuvanted reduced antigen content of inactivated poliovirus vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sii Licensed IPV
Description: Poliomyelitis Vaccine (Inactivated), produced by Serum Institute of India Pvt. Ltd., is a sterile suspension of three types of inactivated poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Poliomyelitis Vaccine (Inactivated) is a highly purified, inactivated poliovirus vaccine.
Study: NCT06110819

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: Pregnant women will be contacted by phone and the status of their follow-up in health institutions will be questioned. During these follow-ups, training is provided and monitoring is carried out in line with the Prenatal Care Management Guide of the Ministry of Health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workgroup
Description: Experimental:~.In line with the Prenatal Care Management Guide of the Ministry of Health, each pregnant woman will be trained and monitored during their trimester until they give birth (4 follow-ups). Pregnancy training trimesters of all participants will be given in accordance with the health guide and follow-up will be done in their living spaces. During these trainings, they will be provided with care in line with the recommendations of the Ministry of Health.
Study: NCT05421039

Intervention type: BEHAVIORAL
Intervention: Exposure to unintended injuries
Description: After taking a verbal consent , an explanation of the study will be given to the caregivers~, those who fulfill the inclusion criteria will be enrolled in the study. Personal interviews by the researcher will be made with individuals or groups (2-4 persons) , participants will be chosen by means of systematic random sampling among visitors ؛ every 3rd or 5th child according to density and flow of attendance .~the investigator will fill the questionnaire through personal interview with the caregivers
Study: NCT05452564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
Study: NCT06533215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.
Description: The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.
Description: The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antimicrobial efficacy of nano based intracanal medications on Enterococcus faecalis count reduction in secondary endodontic infection cases.
Description: The paper points of three samples (S1, S2, and S3) will be placed each in a sterile falcon tube containing 1ml of brain heart infusion and labeled according to the type of intracanal medication used. Samples will be homogenized by the vortex and and one micron of each sample will be cultured on Bile Esculin Agar for E. faecalis.~The plate will be labeled as the tube of the same sample and incubated at 37οC for 24-48 h and then after incubation, the total numbers of E.faecalis will be counted and calculated to get the colony forming units (CFU/ml).
Study: NCT05143554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auricular percutaneous neurostimulation
Description: Percutaneous neurostimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham percutaneous neurostimulation
Description: Sham percutaneous neurostimulation
Study: NCT06515249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine
Description: Integrative medicine treatments including acupuncture, touch, movement, mind-body, as patient\&#39;s and staff\&#39;s choice
Study: NCT06522412

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: JING SI HERBAL TEA LIQUID PACKETS
Description: JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JING SI HERBAL TEA LIQUID PACKETS
Description: JING SI HERBAL TEA LIQUID PACKETS contains: eight herbal ingredients, primarily including dwarf lilyturf, houttuynia, balloon flower, siegesbeckia, licorice, mugwort, perilla leaf, and chrysanthemum. These eight Taiwanese native herbs are known for their abilities to moisturize, disperse cold, relieve lung congestion, dissolve phlegm, remove dampness, and clear heat.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: JING SI HERBAL TANG HENG POWDER DRINK
Description: JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JING SI HERBAL TANG HENG POWDER DRINK
Description: JING SI HERBAL TANG HENG POWDER DRINK contains: Based on the eight herbal ingredients of Jingsi Herbal Drink Concentrate, this drink additionally includes pumpkin powder and bitter melon extract powder. (Ingredients: siegesbeckia, Jingsi complex herbal powder (dextrin fiber, herbal extracts (mugwort, siegesbeckia, dwarf lilyturf, houttuynia, balloon flower, licorice, perilla leaf, chrysanthemum)), pumpkin powder, bitter melon extract powder (bitter melon extract (containing bitter melon peptides), maltodextrin), black pepper, chromium nicotinate complex (chromium nicotinate, sodium chloride)).
Study: NCT05876260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Greek yogurt
Description: Following 2 days of controlled diet, participants will consume greek yogurt following high-intensity interval exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate-based study supplement
Description: Following 2 days of controlled diet, participants will consume a carbohydrate-based study supplement following high-intensity interval exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Following 2 days of controlled diet, participants will perform high-intensity interval exercise following an overnight fast
Study: NCT06133829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: upREACH Home Visitation Program
Description: upREACH is a brief perinatal home visitation program delivered by community health workers or similarly qualified personnel. The mission statement of the program is: Families are prepared to bring home their newborn to a safe, stable, and nurturing environment, and have access to tools, resources, and knowledge that promote family health and well-being. Through the program, families will receive a minimum of 2 home visits during pregnancy and/or postpartum from a home visitor (community health worker (CHW) or similarly qualified personnel). The home visitor will assess each family's strengths and needs so they may provide tailored support and brief education to promote maternal health and self-care, infant health and safety, and connection to and knowledge of resources (community orientation).
Study: NCT06328075

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study

Intervention type: OTHER
Intervention: non interventional study
Description: non interventional study
Study: NCT05099757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: one-dose, two-dose or three-dose, 20 µg per dose
Study: NCT06385262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 300 mg subcutaneously every 4 weeks prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350mg IV every 3 weeks prior to surgery
Study: NCT06083311

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants in this arm will receive a daily dose of 3x10\^9 Colony Forming Units (CFU) of a live bacterium, corresponding to 1 capsules daily for 28 days
Study: NCT06385262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350mg IV every 3 weeks prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Treating provider's choice of FDA approved platinum doublet chemotherapy IV every 3 weeks prior to surgery
Study: NCT06083311

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive an equivalent placebo for 28 days
Study: NCT05053139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0365-3769 (Mim8)
Description: Mim8 will be injected into a skinfold on the stomach with a thin needle either once a week or once a month.
Study: NCT05500508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT1501
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMXT1501
Description: AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 200 mg (free base content) enterically-coated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFMO
Description: DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate provided as a 200 mg/mL aqueous solution in 20 mL vials.
Study: NCT05690828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: The cognitive remediation programme shall be run either in video workshops or face to face workshops and in home sessions via a web app. The programme will run for 4 months during which there will be 3 different evaluations. A first evaluation after randomisation, a second evaluation 4 months after inclusion (corresponding to the end of the programme), and a third evaluation 8 months after inclusion for the experimental group (4 months after the end of the programme). The face to face workshops will take 8 to 10 participants and will be led by a neuropsychologist.
Study: NCT04646460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed Success
Description: The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed Success
Description: The demonstrator in video gets a placebo treatment, Levoderm analgesic cream, which will be shown to be effective at relieving pain.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed Failure
Description: The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
Study: NCT05323721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine and amodiaquine
Description: This is where children 3-59 months will receive SPAQ for SMC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Description: This is where children 3-59 months will receive DP for SMC
Study: NCT04646460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observed Failure
Description: The demonstrator in the video gets the same placebo treatment, but shows little to no effectiveness from the placebo for relieving pain.
Study: NCT05023720

Intervention type: OTHER
Intervention: nonintervention

Intervention type: OTHER
Intervention: nonintervention
Study: NCT04646460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experienced Success
Description: The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experienced Success
Description: The participant will receive reduced stimulus intensities after the placebo cream treatment to reinforce the effectiveness of the cream.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experienced Failure
Description: The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experienced Failure
Description: The participant will not receive reduced stimulus intensities after the placebo treatment, so the cream is not reinforced as effective.
Study: NCT06026254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMSA101
Description: Intra-tumoral administration on Days 1 and 15 of every 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitor
Description: Administered according to product label
Study: NCT04913259

Intervention type: OTHER
Group type: OTHER
Intervention: Remote monitoring
Description: Online remote monitoring tool during the care of patients over the age of 65 who are receiving medical treatment for cancer
Study: NCT05953740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5720
Description: MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5720
Description: MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5720
Description: MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5720
Description: MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5720
Description: MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5720
Description: MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-5720
Description: Placebo matched to MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-5720
Description: Placebo matched to MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-5720
Description: Placebo matched to MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-5720
Description: Placebo matched to MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-5720
Description: Placebo matched to MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-5720
Description: Placebo matched to MK-5720 IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189 tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-8189
Description: Placebo tablet matched to MK-8189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-8189
Description: Placebo tablet matched to MK-8189
Study: NCT04965831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: Furmonertinib 80mg/d as neoadjuvant therapy for 8 weeks before surgery, then as adjuvant therapy for 3 years after surgery.
Study: NCT06627855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Distortion Model
Description: The following techniques were used on the cranial and cervical areas during therapy: Trigger band technique, herniated trigger point technique, continuum technique, folding technique, cylinder technique, and tectonic technique.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The techniques in the therapy will be applied by imitating the techniques in the therapy for the fascial distortions determined according to the Manual Therapy Based on the Fascial Distortion Model.
Study: NCT05953740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-8189
Description: Placebo tablet matched to MK-8189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-8189
Description: Placebo tablet matched to MK-8189